Company Focus

Roche

Latest Roche News

Neuromuscular disease market poised for rapid growth
Pharmaceutical
The global market for neuromuscular disease therapeutics is projected to expand by $13.7 billion from 2025 to 2029, according to a report by Technavio.   16 January 2025


Latest News & Features of interest to Roche

Latest In Brief for Roche

Pharmaceutical
Privately-held US biopharma Bluejay Therapeutics has announced that its lead product candidate brelovitug—also known as BJT-778—has received US Food and Drug Administration Breakthrough Therapy designation for the treatment of chronic hepatitis D.   22 January 2025

Latest Related Ones To Watch News

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered under Medicare Part D for price negotiations. US antiviral giant Gilead Sciences is broadening its therapeutics focus with a deal for LEO Pharma’s small molecule oral STAT6 program in the area of inflammatory diseases.US healthcare giant Johnson & Johnson announced its planned $14.6 billion acquisition of Intra-Cellular Therapies, along with its already marketed CNS drug Caplyta. USA-based Keros Therapeutics revealed it is termination another Phase II study of its pulmonary arterial hypertension (PAH) candidate cibotercept. Also, Italy’s Newron Pharmaceuticals out-licensed its CNS drug evenamide to South Korea’s Myung In Pharma, having just recently licensed the drug to EA Pharma, a unit of Japan’s Eisai.   19 January 2025

More in M&A >


Related Ones to Watch Companies

Reset all filters
Refine Search